Enteris plans to grow through its feasibility-to-licensing strategy in which it works jointly with pharma companies to leverage its Peptelligence platform to develop oral versions of peptides and difficult-to-deliver small molecule drugs. Enteris has several active programs ongoing, including a development agreement with Cara Therapeutics, which recently announced positive Phase I data for an oral version of CR845, a novel peripherally-acting kappa opioid agonist.
Brian Zietsman, president and chief financial officer of Enteris BioPharma, commented, "We are extremely pleased to welcome Tim to our executive team and look forward to benefitting from his extensive experience and acumen. Not only do we anticipate Tim enabling us to rapidly advance our feasibility-to-licensing strategy, but bringing aboard an industry veteran of Tim's caliber serves to firmly establish Enteris as a partner-of-choice for large and small pharma alike."
Most recently, Mr. Saxon was an associate partner with Alacrita Consulting. Prior to Alacrita, he was vice president, Business Development for Arecor Ltd., a drug delivery technology company. He also held business development positions at Novartis, Wyeth, Sagentia Ltd., Boots Pharmaceuticals (now Abbott), and ICI Pharmaceuticals (now AstraZeneca).